Efficacy and Safety of Nab-Paclitaxel in the Treatment of Metastatic Breast Cancer: A Real-Life Experience

Aims: Evaluate safety and efficacy of nab-paclitaxel in pre-treated metastatic breast cancer (MBC) patients in a real-life setting. Patients and Methods: This single centre perspective non-comparative trial evaluated MBC patients treated with nab-paclitaxel. Primary endpoint was safety. Secondary endpoints were: overall response rate, progression free survival (PFS) and overall survival (OS). Results: 31 patients were enrolled. The main toxicities were fatigue (78%), pain (52%), neutropenia (42%) and febrile neutropenia (36%). The median OS was 10.2 months and median PFS was 4.5 months. A partial response was observed in 19.3% of patients and a stable disease in 38.7% of cases; the clinical benefit rate was 58%. Conclusions: Nab-paclitaxel represents a valid therapeutic option for the treatment of highly pre-treated MBC patients.